welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates P...Cancer Prevention Pharmaceuticals, Inc. ...
Recurrences are Common after Endoscopic Ampullectomy for Adenoma in the Familial Adenomatous Polyposis (FAP) Syndrom...BACKGROUND: Endoscopic ampullectomy is ...
Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal CancerExecutive Summary Colorectal Cancer con...
Carcinoma Colon and Managementhttp://www.slideshare.net/shivkishor/car...
Duodenal Mucosal Risk Markers in Patients with Familial Adenomatous Polyposis: Effects of Celecoxib/Ursodeoxycholic ...BACKGROUND : Familial adenomatous polypo...
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/su...Cancer Prevention Pharmaceuticals, Inc. ...